

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2022-23

Date: 10.08.2022

**BSE Limited**  
Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

**Sub. : Outcome of Board Meeting**

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2022.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2022 as **Annexure-A** and
- Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**
- An Investor release on the financial results is enclosed as **Annexure-C**

Further Board of Directors at their meeting approved the following resolutions:

- Approved draft Annual Report for the financial year 2021-22.
- The 29<sup>th</sup> AGM of the Company will be held on Tuesday, September 27, 2022 at 11.00 AM at ISKCON Auditorium, Hare Krishna Hill, Sant Nagar Main Road, East of Kailash, New Delhi-110065.
- Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Tuesday, September 20, 2022 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialised form) to cast their vote electronically from September 24, 2022 (9:00 am) and ends on September 26, 2022 (5:00 pm).
- In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Rs. 1 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2021-22. The aforesaid register will remain close from September 21, 2022 to September 27, 2022 (both days inclusive)



The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.35 p.m.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2022, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

This is for your information and records.

Thanking You.

Yours faithfully,

**For Medicamen Biotech Limited**



**Parul Choudhary**  
Company Secretary  
ACS44157



## MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com


Un-audited Standalone and Consolidated Financial Results for the quarter ended on 30th June' 2022

PART I		Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		31.03.2022	
1	Particulars	3 Months Ended	Preceding	Corresponding	31.03.2022	3 Months Ended	Preceding	Corresponding	31.03.2022
		30.06.2022	3 Months Ended	3 Months Ended		30.06.2022	3 Months Ended	3 Months Ended	
		Un-audited	Audited	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited
1	Income from operations								
	(a) Net Sales / Income from operations	3,308.80	2,275.38	2,753.03	11,544.52	3,308.80	2,275.38	2,753.03	11,544.52
	(b) Other Income	96.23	33.76	7.87	172.01	96.23	33.76	7.87	172.01
	(c) Total Revenue	3,405.03	2,309.14	2,760.90	11,716.53	3,405.03	2,309.14	2,760.90	11,716.53
2	Expenses								
	a) Cost of Material Consumed	1,690.39	1,091.86	1,224.52	5,569.07	1,690.39	1,091.86	1,224.52	5,569.07
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(0.93)	(40.61)	3.39	(333.63)	(0.93)	(40.61)	3.39	(333.63)
	d) Employees Benefits Expenses	434.18	384.30	292.46	1,450.19	434.18	384.30	292.46	1,450.19
	e) Finance Cost	76.72	56.39	4.41	140.06	76.72	56.39	4.41	140.06
	f) Depreciation and Amortisation Expenses	152.72	152.41	132.97	577.14	152.72	152.41	132.97	577.14
	g) Other expenses	619.45	341.95	628.57	2,503.35	619.45	342.89	628.57	2,504.29
	Total Expenses	2,972.53	1,986.30	2,286.33	9,906.18	2,972.53	1,987.23	2,286.33	9,907.11
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	432.50	322.84	474.57	1,810.35	432.50	321.91	474.57	1,809.42
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	432.50	322.84	474.57	1,810.35	432.50	321.91	474.57	1,809.42
6	Tax Expenses								
	Current Year	97.88	53.45	66.03	397.69	97.88	53.45	66.03	397.69
	MAT Credit Entitlement	-	-	-	-	-	-	-	-
	Deferred Tax Liability	(23.93)	(6.08)	(6.59)	(77.98)	(23.93)	(6.08)	(6.59)	(77.98)
	Total Tax Expense	73.94	47.37	59.44	319.71	73.94	47.37	59.44	319.71
7	Net Profit /Loss for the period from Continuing operation (5- 6)	358.56	275.47	415.13	1,490.64	358.56	274.54	415.13	1,489.71
8	Other Comprehensive Income								
	Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-
9	Total Comprehensive Income net of Tax	358.56	275.47	415.13	1,490.64	358.56	274.54	415.13	1,489.71
10	Paid up equity share capital (Rs. 10/- per share)	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66
11	Earning Per Share (Rs.)								
	Basic	2.94	2.25	3.40	12.20	2.94	2.25	3.40	12.19
	Diluted	2.94	2.25	3.40	12.20	2.94	2.25	3.40	12.19

### NOTES :

- 1 The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10.08.2022
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- 5 The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities which is visible from increased finance cost. The company has also recruited and placed senior human resources for the purpose of creating its own marketing network in francophone Africa. The company shall start reaping its benefits from next financial year.
- 6 Limited review report has been carried out by the Statutory Auditors for the above period.
- 7 The Figures for the quarter ended 31 March 2022 is the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
- 8 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors  
Medicamen Biotech Limited



(Rahul Bishnoi)  
Chairman

Place : New Delhi  
Dated : 10.08.2022

# RAI QIMAT & ASSOCIATES

## CHARTERED ACCOUNTANTS



**INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To

**The Board of Directors,  
Medicamen Biotech Limited  
1506, Chiranjiv Tower 43,  
Nehru Place, New Delhi- 110019**

1. We have reviewed the Unaudited Consolidated Financial Results of Medicamen Biotech Limited (the "Parent Company"), and the Subsidiary Company for the quarter and three months ended on June 30, 2022 which are included in the accompanying 'Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2022 (the "Statement")'. The Statement is being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd (the "Subsidiary" Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to

be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates  
Chartered Accountants



UDIN- 22080857AORWEQ7177

Place: Gurugram  
Date: 10.08.2022



**INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED  
QUARTERLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE  
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE  
REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To

The Board of Directors,  
**Medicamen Biotech Ltd.**  
1506, Chiranjiv Tower, 43,  
Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and three months ended June 30, 2022 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates  
Chartered Accountants



UDIN- 22080857AORWEQ7177

Place: Gurugram  
Date: 10.08.2022



# Investor Presentation

---

Medicamen Biotech Limited



Committed for **affordable quality**  
through **improvement and technology**

# Safe Harbour Statement

This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward looking statements. These factors include, but are not limited to, domestic and global economic and business conditions, the successful implementation of our strategy and our ability to realize the benefits of this strategy, our ability to develop and market new products, etc. As a result, MBL’s actual future results may differ materially from the plans, goals and expectations set forth in such forward looking statements. MBL does not undertake any obligation to update such forward looking statements to reflect events or circumstances after the date thereof.



# Medicamen Biotech Limited – An overview

## An Overview of Company



- Medicamen Biotech was established in 1996 and is engaged in manufacturing of diverse range of pharmaceutical products Oral Solids, Oral Liquids, ointment for non-oncology products range and it also produces tablet, capsule/lyophilized/dry powder injections for oncology product range.
- MBL has three state of art manufacturing facility is located at Bhiwari (Rajasthan) and two of its plants are located at Haridwar (Uttarakhand).
- Bhiwadi Plant is spread over in a sprawling area of 20625 sqm, having approx. 12000 sqm of constructed area divided into 8 different blocks.
- Bhiwadi Plant is “WHO” GMP approved, and ISO certified.
- Medicamen has its second plant at SIDCUL Haridwar, for domestic market. This plant has recently got WHO GMP Certification. The plant has been audited by Ethiopian Authorities in the month of June has got approval on 4<sup>th</sup> August 2022. This plant is basically for Ointment and Cream.
- Medicamen has set up its third State of Art ONCOLOGY FORMULATIONS Plant at Haridwar which has started the commercial production from this year. This plant has recently got WHO GMP Certification. This plant is USFDA compliant and aims to cater to regulated market like US, EU, UK and Japan etc.

# Medicamen Biotech Limited



## Current Business

- **MBL's Bhiwadi plant is approved in more than 30 countries having around 125 product registrations.**
- **Currently company is working with over 150 SKU across 20 different therapeutic segments.**
- **Top Therapeutic segments include Antibiotics, Antifungal, Anti pain management, Analgesics and Anti malaria, forming around 80% of Revenue.**
- **Currently MBL is into exports only, 80% of Revenue comes from Direct Exports and rest comes from merchant Exports. The majority of the revenue is from African region, Latin America and Southeast Asia.**

# Global Presence



# Future Growth Plan – Oncology Segment

- Started ethical marketing of the Oncology products in India with a team of 25 senior executives in four zones.
- MBL has launched three Oncology products in the month of January, and it has already launched eight products as on date.
- MBL has plans to file two ANDA's during the current financial year.
- Targeted market for Oncology would be regulated as well as semi regulated markets.

For the use of registered medical practitioner, laboratory or hospital only.

**VIVO Oncology**  
Quality Cancer Care

**ABTmed™**  
Hetero. 2015.12.17

**PROSTATE CANCER**

**Child-Resistant Packaging**

**State-of-the-Art Manufacturing Facilities** dedicated for Oncology, APIs & Formulations, compliant to cGMP, USFDA, EU GMP

**Global Quality Standards**

**Ensuring Patient Safety**

**Global presence in more than 35 countries**

**Transforming Lives... Through Quality**

**Radiamed™**  
Unlicensed Prescription

**SUPPORTIVE CARE**

**Focus Therapy Areas**  
Haematology Cancer  
Breast Cancer  
Lung Cancer  
Thyroid Cancer  
Renal Cancer  
Prostate Cancer  
Brain Tumour  
Supportive Care

**MB MEDICAMEN Biotech Limited**  
Corporate office & Regd. office:  
208, Changan Road, 4th Floor, New Delhi - 110003, India  
Ph. No. +91 11 2626542 / +91 11 2626503  
E-mail: global.oncology@medicamen.com & info@medicamen.com  
Website: www.medicamen.com www.ab-vaik-rasagar.com

**MB MEDICAMEN Biotech Limited**

For more info, scan the code.

# Future Growth Plan – Product Profile

**For Hand Foot Syndrome**

**VIVO Oncology**  
Quality Cancer Care

**INTRODUCING**  
**Radiamed™**  
Urea, Lactic Acid & Glycerin Cream  
**Cream**  
*Safe, Effective & Affordable*

**Improves QoL and Aids cancer patients continue chemotherapy**




**VIVO Oncology**  
Quality Cancer Care

**In metastatic NSCLC & locally advanced Pancreatic Cancer**

**INTRODUCING**  
**ETBmed™**  
Erlotinib Tablets IP 100 mg / 150 mg  
*Effectively Blocks EGFR*

**Patients who received chemotherapy with erlotinib and achieved major pathological responses had excellent clinical outcome<sup>1</sup>**

Ref: 1. Clin Cancer Res clincanres.3239. 2021



# Future Growth Plan – Product Profile


**INTRODUCING**  
In DTC, HCC, RCC  
& Endometrial Cancer

**Lenvamed™**  
Lenvatinib Capsules 4 mg / 10 mg

**LIFTING HOPE**

**Indications**

- Differentiated Thyroid Carcinoma (DTC)
- Renal Cell Carcinoma (RCC)
- Unresectable Hepatocellular carcinoma (HCC)
- Endometrial Cancer



**INTRODUCING**  
In the treatment of advanced or  
metastatic renal cell carcinoma (mRCC)

**PAZOCAM™**  
Pazopanib Hydrochloride Tablets 200 mg / 400 mg

*Prolongs Life*

# Future Growth Plan – Product Profile

INTRODUCING

Rx **Capivo**<sup>TM</sup>

*Carrying Hope*

Capecitabine Tablets IP 150 mg / 500 mg



In the treatment of Multiple Myeloma  
& Mantle Cell Lymphoma

Rx **Borzomed**<sup>TM</sup>

Bortezomib Injection 2 mg / 2.5 mg / 3.5 mg per vial

*Bringing life to life*



# Future Growth Plan-Marketing Network in Africa

- MBL intends to create its own marketing network in ten Francophone countries by using distributing network of Euro Pharma, Paris which holds 11% equity in MBL.
- MBL intends to market 100 branded products in this territory for which the brands have been finalized.
- MBL has a target to file 100 dossiers in each of ten francophone countries making total 1000 dossier in all.

- 
- MBL has already recruited a senior executive who is based in Ghana, the marketing companies have also been shortlisted, who will handle its marketing operation in these Francophone countries.
  - Currently MBL has 23 registered products in Ethiopia and is aiming to register 100 products by this financial year end.
  - Apart from this MBL is also filing dossiers in Zimbabwe, Tanzania.



# Thank you!

---

## Medicamen Biotech Limited

**REGISTERED OFFICE**

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi - 110019

**Phone** 011-47589500 (30 Lines) | **Fax** 011-26213081 | **E-mail** [cs@medicamen.com](mailto:cs@medicamen.com)

**Website** [www.medicamen.com](http://www.medicamen.com)